Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Wave Life Sciences, Inc.WVE · Entity 4976 | Director | October 05, 2026 | October 08, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Wave Life Sciences, Inc.
Report date October 05, 2026 · Filed October 08, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 200,917 |
Reported balance
After 2026-10-05 transaction · row 1
1 source rowRow 1 · 2026-10-05 · Grant · Acquired 10,700 · Balance 200,917 F1: The reporting person was granted this restricted stock unit award (RSU) pursuant to the 2026 Non-Employee Director Compensation Policy. The RSU vests as to 100% of the shares on the earlier of the Company's 2027 annual meeting of stockholders or October 5, 2027. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.75 · Expires 2036-10-05 | Direct | 64,000 |
Reported balance
After 2026-10-05 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-10-05 · Grant · Acquired 64,000 · Balance 64,000 F3: The reporting person was granted this option pursuant to the 2026 Non-Employee Director Compensation Policy. The option vests as to 100% of the shares on the earlier of the Company's 2027 annual meeting of stockholders or October 5, 2027. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 75,000 |
Reported balance
Holding disclosure · report date 2026-10-05 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 75,000 F2: Consists of shares of common stock held in a trust by Lynet Holdings LLC. The reporting person is the sole manager of Lynet Holdings LLC and the settlor of the trust and may be deemed to have shared voting and investment power over the shares. The reporting person disclaims beneficial ownership of the shares held except to the extent of his pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: The reporting person was granted this restricted stock unit award (RSU) pursuant to the 2026 Non-Employee Director Compensation Policy. The RSU vests as to 100% of the shares on the earlier of the Company's 2027 annual meeting of stockholders or October 5, 2027.
F2: Consists of shares of common stock held in a trust by Lynet Holdings LLC. The reporting person is the sole manager of Lynet Holdings LLC and the settlor of the trust and may be deemed to have shared voting and investment power over the shares. The reporting person disclaims beneficial ownership of the shares held except to the extent of his pecuniary interest therein.
F3: The reporting person was granted this option pursuant to the 2026 Non-Employee Director Compensation Policy. The option vests as to 100% of the shares on the earlier of the Company's 2027 annual meeting of stockholders or October 5, 2027.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 05, 2026 Filed Oct 8, 2026 01:00 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | GrantStock Option (right to buy) · Derivative | 64,000 | $0.00 Strike: $3.75 | $0.00 |
DisclosureSEC source: 0001193125-26-417237 · ownership.xml · derivative · entry 3 Verdine Gregory L. · CIK 0001572315 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 64,000 Underlying: Common Stock · 64,000 shares Expires 2036-10-05 F3 · derivative.exercise_date: The reporting person was granted this option pursuant to the 2026 Non-Employee Director Compensation Policy. The option vests as to 100% of the shares on the earlier of the Company's 2027 annual meeting of stockholders or October 5, 2027. Read SEC document |
| October 05, 2026 Filed Oct 8, 2026 01:00 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | GrantCommon Stock | 10,700 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-417237 · ownership.xml · nonDerivative · entry 1 Verdine Gregory L. · CIK 0001572315 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 200,917 F1 · shares: The reporting person was granted this restricted stock unit award (RSU) pursuant to the 2026 Non-Employee Director Compensation Policy. The RSU vests as to 100% of the shares on the earlier of the Company's 2027 annual meeting of stockholders or October 5, 2027. Read SEC document |
| December 08, 2025 Filed Dec 10, 2025 21:45 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | SaleOrdinary Shares | 7,980 | $14.05 | $112,119.00 |
DisclosureSEC source: 0001193125-25-314738 · ownership.xml · nonDerivative · entry 2 Verdine Gregory L. · CIK 0001572315 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 275,217 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 13, 2025. F3 · price: The price reflected is the weighted-average sale price for shares sold. The shares were sold in multiple transactions and the range of sale prices for the transactions reported was $13.75 to $14.70 per share. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price Read SEC document |
| December 08, 2025 Filed Dec 10, 2025 21:45 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | SaleOrdinary Shares | 12,020 | $13.09 | $157,341.80 |
DisclosureSEC source: 0001193125-25-314738 · ownership.xml · nonDerivative · entry 1 Verdine Gregory L. · CIK 0001572315 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 283,197 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 13, 2025. F2 · price: The price reflected is the weighted-average sale price for shares sold. The shares were sold in multiple transactions and the range of sale prices for the transactions reported was $12.75 to $13.74 per share. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. Read SEC document |
| August 22, 2025 Filed Aug 26, 2025 21:40 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | SaleOrdinary Shares | 10,000 | $10.00 | $100,000.00 |
DisclosureSEC source: 0000950170-25-111568 · ownership.xml · nonDerivative · entry 1 Verdine Gregory L. · CIK 0001572315 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 285,217 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 13, 2025. Read SEC document |
| August 11, 2025 Filed Aug 13, 2025 20:00 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | GrantShare Option (right to buy) · Derivative | 76,200 | $0.00 Strike: $8.11 | $0.00 |
DisclosureSEC source: 0000950170-25-108285 · ownership.xml · derivative · entry 2 Verdine Gregory L. · CIK 0001572315 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 76,200 Underlying: Ordinary Shares · 76,200 shares Expires 2030-08-11 F2 · derivative.exercise_date: The reporting person was granted this option pursuant to the 2025 Non-Employee Director Compensation Policy. The option vests as to 100% of the shares on the earlier of the Company's 2026 annual general meeting or August 11, 2026. Read SEC document |
| August 11, 2025 Filed Aug 13, 2025 20:00 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | GrantOrdinary Shares | 12,700 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-108285 · ownership.xml · nonDerivative · entry 1 Verdine Gregory L. · CIK 0001572315 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 295,217 F1 · shares: The reporting person was granted this restricted share unit award (RSU) pursuant to the 2025 Non-Employee Director Compensation Policy. The RSU vests as to 100% of the shares on the earlier of the Company's 2026 annual general meeting or August 11, 2026. Read SEC document |
| June 13, 2025 Filed Jun 13, 2025 20:00 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | SaleOrdinary Shares | 30,000 | $6.95 | $208,500.00 |
DisclosureSEC source: 0000950170-25-086466 · ownership.xml · nonDerivative · entry 1 Verdine Gregory L. · CIK 0001572315 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 282,517 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 13, 2025. F2 · price: The price reflected is the weighted-average sale price for shares sold. The shares were sold in multiple transactions and the range of sale prices for the transactions reported was $6.79 to $7.04 per share. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. Read SEC document |
| March 07, 2025 Filed Mar 7, 2025 21:00 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | Exercise / conversionShare Option (right to buy) · Derivative | 133,402 | $0.00 Strike: $2.48 | $0.00 |
DisclosureSEC source: 0000950170-25-035834 · ownership.xml · derivative · entry 4 Verdine Gregory L. · CIK 0001572315 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 133,402 shares Expires 2025-03-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The share options that were exercised via cash purchase in this reportable transaction were fully vested. Read SEC document |
| March 07, 2025 Filed Mar 7, 2025 21:00 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | Exercise / conversionOrdinary Shares | 133,402 | $2.48 | $330,836.96 |
DisclosureSEC source: 0000950170-25-035834 · ownership.xml · nonDerivative · entry 2 Verdine Gregory L. · CIK 0001572315 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 312,517 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 05, 2025 Filed Mar 7, 2025 21:00 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | Exercise / conversionShare Option (right to buy) · Derivative | 133,000 | $0.00 Strike: $2.48 | $0.00 |
DisclosureSEC source: 0000950170-25-035834 · ownership.xml · derivative · entry 3 Verdine Gregory L. · CIK 0001572315 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 133,402 Underlying: Ordinary Shares · 133,000 shares Expires 2025-03-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The share options that were exercised via cash purchase in this reportable transaction were fully vested. Read SEC document |
| March 05, 2025 Filed Mar 7, 2025 21:00 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | Exercise / conversionOrdinary Shares | 133,000 | $2.48 | $329,840.00 |
DisclosureSEC source: 0000950170-25-035834 · ownership.xml · nonDerivative · entry 1 Verdine Gregory L. · CIK 0001572315 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 179,155 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 12, 2024 Filed Aug 14, 2024 18:00 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | GrantShare Option (right to buy) · Derivative | 32,230 | $0.00 Strike: $5.37 | $0.00 |
DisclosureSEC source: 0000950170-24-097285 · ownership.xml · derivative · entry 2 Verdine Gregory L. · CIK 0001572315 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,230 Underlying: Ordinary Shares · 32,230 shares Expires 2029-08-12 F2 · derivative.exercise_date: The reporting person was granted this option pursuant to the 2024 Non-Employee Director Compensation Policy. The option vests as to 100% of the shares on the earlier of the Company's 2025 annual general meeting or August 12, 2025. Read SEC document |
| August 12, 2024 Filed Aug 14, 2024 18:00 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | GrantOrdinary Shares | 16,115 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-097285 · ownership.xml · nonDerivative · entry 1 Verdine Gregory L. · CIK 0001572315 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 46,115 F1 · shares: The reporting person was granted this restricted share unit award (RSU) pursuant to the 2024 Non-Employee Director Compensation Policy. The RSU vests as to 100% of the shares on the earlier of the Company's 2025 annual general meeting or August 12, 2025. Read SEC document |
| August 07, 2023 Filed Aug 9, 2023 20:00 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | GrantShare Option (right to buy) · Derivative | 45,000 | $0.00 Strike: $4.58 | $0.00 |
DisclosureSEC source: 0000899243-23-017910 · doc4.xml · derivative · entry 1 Verdine Gregory L. · CIK 0001572315 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 45,000 Underlying: Ordinary Shares · 45,000 shares Expires 2028-08-07 F1 · derivative.exercise_date: The reporting person was granted this option pursuant to the Non-Employee Director Compensation Policy. The option vests as to 100% of the shares on the earlier of the Company's 2024 annual general meeting or August 7, 2024. Read SEC document |
| October 27, 2022 Filed Oct 28, 2022 20:00 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | GrantShare Option (right to buy) · Derivative | 163,467 | $0.00 Strike: $4.37 | $0.00 |
DisclosureSEC source: 0000899243-22-034493 · doc4.xml · derivative · entry 1 Verdine Gregory L. · CIK 0001572315 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 163,467 Underlying: Ordinary Shares · 163,467 shares Expires 2027-10-27 F1 · derivative.exercise_date: The reporting person was granted this option pursuant to his existing consulting agreement with Wave. The option vests in equal monthly installments beginning on October 31, 2022, through December 31, 2024, subject to the reporting person's continued services through the applicable vesting date. Read SEC document |
| August 15, 2022 Filed Aug 17, 2022 20:01 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | GrantShare Option (right to buy) · Derivative | 21,000 | $0.00 Strike: $3.50 | $0.00 |
DisclosureSEC source: 0000899243-22-029098 · doc4.xml · derivative · entry 1 Verdine Gregory L. · CIK 0001572315 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,000 Underlying: Ordinary Shares · 21,000 shares Expires 2027-08-15 F1 · derivative.exercise_date: The reporting person was granted this option pursuant to the Non-Employee Director Compensation Policy. The option vests as to 100% of the shares on the earlier of the Company's 2023 annual general meeting or August 15, 2023. Read SEC document |
| August 16, 2021 Filed Aug 18, 2021 18:12 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | GrantShare Option (right to buy) · Derivative | 42,000 | $0.00 Strike: $5.97 | $0.00 |
DisclosureSEC source: 0000899243-21-033528 · doc4.xml · derivative · entry 1 Verdine Gregory L. · CIK 0001572315 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,000 Underlying: Ordinary Shares · 42,000 shares Expires 2026-08-16 F1 · derivative.exercise_date: The reporting person was granted this option pursuant to the Non-Employee Director Compensation Policy. The option vests as to 12.5% of the shares in equal quarterly installments over the two-year period following the grant date on August 16, 2021. Read SEC document |
| August 18, 2020 Filed Aug 20, 2020 18:34 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | GrantShare Option (right to buy) · Derivative | 10,500 | $0.00 Strike: $9.13 | $0.00 |
DisclosureSEC source: 0000899243-20-023089 · doc4.xml · derivative · entry 1 Verdine Gregory L. · CIK 0001572315 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,500 Underlying: Ordinary Shares · 10,500 shares Expires 2025-08-18 F1 · derivative.exercise_date: The reporting person was granted this option pursuant to the Non-Employee Director Compensation Policy. The option vests as to 100% of the shares on the earlier of the Company's 2021 annual general meeting or August 18, 2021. Read SEC document |
| November 20, 2019 Filed Nov 22, 2019 17:49 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | SaleOrdinary Shares | 2,609 | $32.74 | $85,418.66 |
DisclosureSEC source: 0000899243-19-027985 · doc4.xml · nonDerivative · entry 3 Verdine Gregory L. · CIK 0001572315 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 F3 · price: The price reflected is the weighted-average sale price for shares sold. The shares were sold in multiple transactions and the range of sale prices for the transactions reported was $32.69 to $32.76 per share. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. Read SEC document |
| November 20, 2019 Filed Nov 22, 2019 17:49 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | SaleOrdinary Shares | 3,400 | $31.59 | $107,406.00 |
DisclosureSEC source: 0000899243-19-027985 · doc4.xml · nonDerivative · entry 2 Verdine Gregory L. · CIK 0001572315 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,609 F2 · price: The price reflected is the weighted-average sale price for shares sold. The shares were sold in multiple transactions and the range of sale prices for the transactions reported was $31.50 to $32.04 per share. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. Read SEC document |
| November 20, 2019 Filed Nov 22, 2019 17:49 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | SaleOrdinary Shares | 24,030 | $30.27 | $727,388.10 |
DisclosureSEC source: 0000899243-19-027985 · doc4.xml · nonDerivative · entry 1 Verdine Gregory L. · CIK 0001572315 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,009 F1 · price: The price reflected is the weighted-average sale price for shares sold. The shares were sold in multiple transactions and the range of sale prices for the transactions reported was $30.07 to $31.045 per share. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. Read SEC document |
| August 15, 2019 Filed Aug 16, 2019 16:22 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | GrantShare Option (right to buy) · Derivative | 10,500 | $0.00 Strike: $20.34 | $0.00 |
DisclosureSEC source: 0000899243-19-021967 · doc4.xml · derivative · entry 1 Verdine Gregory L. · CIK 0001572315 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,500 Underlying: Ordinary Shares · 10,500 shares Expires 2024-08-15 F1 · derivative.exercise_date: The reporting person was granted this option pursuant to the Non-Employee Director Compensation Policy. The option vests as to 100% of the shares on the earlier of the Company's 2020 annual general meeting or August 15, 2020. Read SEC document |
| November 14, 2018 Filed Nov 16, 2018 17:15 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | SaleOrdinary Shares | 4,300 | $39.52 | $169,936.00 |
DisclosureSEC source: 0000899243-18-029157 · doc4.xml · nonDerivative · entry 2 Verdine Gregory L. · CIK 0001572315 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,039 F2 · price: The price reflected is the weighted-average sale price for shares sold. The shares were sold in multiple transactions and the range of sale prices for the transactions reported was $39.33 to $39.53 per share. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.. Read SEC document |
| November 14, 2018 Filed Nov 16, 2018 17:15 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | SaleOrdinary Shares | 10,700 | $38.59 | $412,913.00 |
DisclosureSEC source: 0000899243-18-029157 · doc4.xml · nonDerivative · entry 1 Verdine Gregory L. · CIK 0001572315 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,339 F1 · price: The price reflected is the weighted-average sale price for shares sold. The shares were sold in multiple transactions and the range of sale prices for the transactions reported was $38.15 to $39.10 per share. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. Read SEC document |
| August 13, 2018 Filed Aug 15, 2018 20:09 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | GrantShare Option (right to buy) · Derivative | 9,000 | $0.00 Strike: $46.70 | $0.00 |
DisclosureSEC source: 0000899243-18-022513 · doc4.xml · derivative · entry 1 Verdine Gregory L. · CIK 0001572315 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,000 Underlying: Ordinary Shares · 9,000 shares Expires 2023-08-13 F1 · derivative.exercise_date: The reporting person was granted this option pursuant to the Non-Employee Director Compensation Policy. The option vests as to 100% of the shares on August 13, 2019. Read SEC document |
| August 10, 2017 Filed Aug 17, 2017 16:19 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | GrantShare Option (right to buy) · Derivative | 9,000 | $0.00 Strike: $18.10 | $0.00 |
DisclosureSEC source: 0000899243-17-020601 · doc4.xml · derivative · entry 1 Verdine Gregory L. · CIK 0001572315 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,000 Underlying: Ordinary Shares · 9,000 shares Expires 2022-08-10 F1 · derivative.exercise_date: The reporting person was granted this option pursuant to the Non-Employee Director Compensation Policy. The option vests as to 100% of the shares on August 10, 2018. Read SEC document |
| August 07, 2017 Filed Feb 14, 2018 19:07 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | GiftOrdinary Shares | 75,040 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-003953 · doc5.xml · nonDerivative · entry 1 Verdine Gregory L. · CIK 0001572315 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,039 Read SEC document |
| November 10, 2016 Filed Nov 14, 2016 17:41 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | GrantShare Option (right to buy) · Derivative | 9,000 | $0.00 Strike: $36.43 | $0.00 |
DisclosureSEC source: 0000899243-16-033354 · doc4.xml · derivative · entry 1 Verdine Gregory L. · CIK 0001572315 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,000 Underlying: Ordinary Shares · 9,000 shares Expires 2021-11-10 F1 · derivative.exercise_date: The reporting person was granted this option pursuant to the Non-Employee Director Compensation Policy. The option vests as to 100% of the shares on November 10, 2017. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.